Biotech News

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.2026-06-25 13:46 ESTCompany update

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and

Open original release

Related news

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

View all latest news

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

FENCFennec Pharmaceuticals Inc.2026-06-26 07:28 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-26 07:28 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-26 07:28 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FENCFennec Pharmaceuticals Inc.2026-06-26 07:28 EST

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-06-26 07:28 EST

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States